<DOC>
	<DOCNO>NCT01305395</DOCNO>
	<brief_summary>1 . Early initiation sirolimus prevent delay development intimal thicken subsequent graft failure . 2 . Treatment guide development cardiac allograft vasculopathy ( CAV ) intravascular ultrasound ( IVUS ) effective delay progression CAV compare treatment guide angiography . 3 . Prevention development progression intimal thickness IVUS prevent development heart failure , graft dysfunction , cardiovascular death relate CAV . 4 . Small artery elasticity predict progression cardiac allograft vasculopathy modify sirolimus 5 . Patients progression CAV favorable improvement biomarkers endothelial cell compare patient progression CAV</brief_summary>
	<brief_title>Strategies To Prevent Cardiac Allograft Vasculopathy Related Events Heart Transplant Recipients</brief_title>
	<detailed_description>Proliferation signal inhibitor ( PSIs ) , sirolimus everolimus , demonstrate effective immunosuppressant delay progression cardiac allograft vasculopathy . To date , prospective study design evaluate potential use PSIs primary immunosuppressant prevention cardiac allograft vasculopathy . The goal study compare primary vs. secondary preventive strategy evaluate role intravascular ultrasound compare coronary angiogram diagnose CAV prevent CAV-related event . The specific aim study : 1 . To evaluate effect primary vs. secondary initiation sirolimus development significant coronary artery ( &gt; 70 % angiographic stenosis , Mean intimal thickness ( MIT ) 0.5mm great , IVUS calculate coronary cross sectional area &lt; 4mm2 / &lt; 6mm2 mid LAD/Left Maim ( LM ) , &lt; 0.75 fractional flow reserve ( FFR ) lesion associate positive stress test ) , change global left ventricle ( LV ) function , incidence rejection episode , hospitalization 1 , 2 , 3 , 4 year . 2 . To determine effect IVUS-guided initiation sirolimus short-term long-term outcome vs. angiogram-guided initiation sirolimus 3 . To determine whether prevention progression CAV diagnose IVUS prevents graft dysfunction death relate CAV heart failure . 4 . To assess correlation peripheral small artery elasticity , peripheral biomarkers , endothelial cell , development cardiac allograft vasculopathy order develop strategy determine risk progression monitoring treatment . The study prospective retrospective arm Prospective Arm Design : This prospective , randomize , partially-blinded pilot study . Randomization study do 2 stage . The first stage randomization randomize subject either early late initiation sirolimus . At stage randomization , subject 30 % chance group 1 ( early-initiation sirolimus ) , 70 % chance group 2 ( diagnostic-guided sirolimus group ) . The second stage randomization do subject group 2 ( diagnostic-guided sirolimus group ) time first annual heart transplant review . At time annual heart transplant review , subject group 2 50 % chance group 2A ( CAV diagnose angiogram ) , 50 % chance group 2B ( CAV diagnose intravascular ultrasound ) . Group 1 : Initiate sirolimus 6 month transplant Group 2A : Initiate sirolimus development angiographic stenosis &gt; 70 % major epicardial vessel &gt; 50 % leave main artery Group 2B : Initiate sirolimus development maximal intimal thickness 0.5 mm intravascular ultrasound Retrospective Arm The main objective retrospective study compare treatment strategy base diagnosis CAV intravascular ultrasound strategy guide angiogram . Design : This randomize , partially-blinded pilot study . Subjects randomize 1:1 one two group . At time randomization , subject 50 % chance group 1 ( initiation sirolimus CAV diagnose angiogram ) 50 % chance group 2 . ( Initiation sirolimus CAV diagnose IVUS ) Primary Endpoints Prospective Retrospective Arms 1 . Change maximal intimal thickness 1 , 2 , 3 4 year 2 . Combination significant coronary artery disease ( describe ) , death , major rejection episode , decrease global ejection function 10 % baseline 3 4years . Secondary endpoint Prospective Retrospective Arms 1 . Mean MIT 1 , 2 , 3 , 4 year 2 . Percent atheroma volume 1,2,3 4 year 3 . Death CAV , death cause , myocardial infarction , need PCI , number hospitalization , infection rate , evidence restrictive physiology , arrhythmic event relate CAV pulmonary hypertension 4 year . 4 . Change small artery elasticity 1 , 2 , 3 , 4 year 5 . Change endothelial progenitor cell count 1 2 year 6 . Change biomarkers ( see table ) 1 2 year</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria For Prospective Arm : 18 year old Successful orthotropic heart transplant within 6 month enrollment Inclusion Criteria For Retrospective Arm : 18 year old Successful orthotropic heart transplant within 6 month 3 year enrolment Less moderate CAV angiogram IVUS Exclusion Criteria For Prospective Arm : Greater minimal baseline coronary disease Chronic kidney disease creatinine &gt; 2mg/dl Baseline ( 1 month ) ejection fraction &lt; 50 % IV contrast allergy Rejection within 3 month enrollment Sensitivity sirolimus derivative Prior sirolimus use Exclusion Criteria For Retrospective Arm : Significant baseline ( one month ) coronary artery disease ( &gt; 50 % one vessel angiogram MIT &gt; 0.5 IVUS ) Chronic kidney disease creatinine &gt; 2mg/dl Baseline ( 1 month ) ejection fraction &lt; 50 % IV contrast allergy Rejection within 3 month prior enrollment Sensitivity sirolimus derivative Prior sirolimus use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cardiac Allograft Vasculopathy Heart Transplant</keyword>
</DOC>